Research progress of medication treatment of dry age-related macular degeneration
Author:
Corresponding Author:

Affiliation:

Clc Number:

Fund Project:

Science and Technology Program of Guangzhou(No.202201020075); Medical Scientific Research Foundation of Guangdong(No.B2023251)

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Age-related macular degeneration(ARMD)is one of the leading causes of irreversible visual impairment worldwide, and the number of patients is increasing with the aging of the population, with dry ARMD accounting for about 90% of cases. Effective treatments for dry ARMD are currently lacking, making it a prominent area of research. Pharmacotherapy, targeting pathogenic factors such as oxidative damage, inflammation, and vascular issues contributing to ARMD, is one of the main treatments and some drugs have been shown to slow the progression of ARMD. This article reviews drug treatments for dry ARMD, including antioxidant drugs, complement biological agents, non-steroidal anti-inflammatory drugs and immunosuppressants, vasodilators, neurotrophic drugs, as well as traditional Chinese medicine. It summarizes their mechanisms and recent clinical research to contribute valuable insights for the treatment of dry ARMD and the development of novel therapeutic agents.

    Reference
    Related
    Cited by
Get Citation

Jie Zhou, Qian-Yin Chen, Jing-Lin Zhang. Research progress of medication treatment of dry age-related macular degeneration. Guoji Yanke Zazhi( Int Eye Sci) 2023;23(11):1835-1839

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:April 13,2023
  • Revised:September 20,2023
  • Adopted:
  • Online: October 24,2023
  • Published: